- Details
- Oliver Sartor joins Alicia Morgans to reflect on prostate cancer data presented during ASCO GU, highlighting data from three studies. Dr. Sartor discusses the phase 3 ARASENS trial, the phase 3 MAGNITUDE study, and the phase 3 PROpel trial. They discuss their perspectives on how these data will inform practice in the future. Biographies: A. Oliver Sartor, MD, Professor of Medicine and Medical Dire...
|
- Details
- Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director, Seattle...
|
- Details
- Alicia Morgans and Fred Saad discuss the ongoing ARANOTE trial, assessing darolutamide and androgen deprivation therapy (ADT), as compared to ADT alone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ARANOTE is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Dr. Saad gives a background on the trial. Biographies: Fred Saad, MD, FRCS...
|
- Details
- Joining Alicia Morgans is Joaquin Mateo to discuss the ZZFIRST trial, examining enzalutamide and talazoparib for the treatment of metastatic hormone-naïve prostate cancer (mHNPC). Dr. Mateo presented the rationale and design for the ZZFIRST trial during the Trials in Progress Poster Session at the 2022 American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium. Biographies: Joaqu...
|
- Details
- Alicia Morgans is joined by Toni Choueiri to discuss his GU ASCO 2022 presentation on a 30-month follow-up from the KEYNOTE-564 trial of post-nephrectomy adjuvant pembrolizumab in patients with renal cell carcinoma (RCC). Dr. Choueiri highlights that adjuvant pembrolizumab continued to demonstrate a disease-free survival (DFS) benefit following nephrectomy for patients with intermediate-high or hi...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospit...
|
- Details
- In this conversation with Alicia Morgans, Daniel Spratt discusses artificial intelligence (AI)-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition o...
|
- Details
- In this discussion, Alicia Morgans converses with Alfredo Berruti. They delve into the findings of the ADIUVO trial, which aimed to evaluate the efficacy of adjuvant mitotane therapy in patients with adrenocortical carcinoma at low to intermediate risk of relapse. Despite the rarity of the disease and challenges in patient enrollment, the trial reveals that adjuvant mitotane does not significantly...
|
- Details
- Alicia Morgans is joined by Felix Feng to discuss an AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy (ADT) in localized prostate cancer with validation in NRG/RTOG 9408. The current standard of care for men with intermediate- and high-risk localized prostate cancer treated with radiotherapy is the addition of ADT. This AI-derived predictive bioma...
|
- Details
- Sam Chang hosts Yohann Loriot to discuss the LEAP-011 study. The study aims to evaluate the combination of pembrolizumab and lenvatinib for treating metastatic urothelial carcinoma in patients ineligible for cisplatin-based chemotherapy. Despite promising preliminary data from the KEYNOTE-146 study, the LEAP-011 trial finds no significant difference in progression-free survival (PFS) or overall su...
|
